| Literature DB >> 35547640 |
Chun Yang1, Sunao Li1, Xinqi Huang1, Xueshi Chen1, Haiyan Shan2, Xiping Chen1, Luyang Tao1, Mingyang Zhang1.
Abstract
Silk fibroin, a natural macromolecular protein without physiological activity, has been widely used in different fields, such as the regeneration of bones, cartilage, nerves, and other tissues. Due to irrevocable neuronal injury, the treatment and prognosis of neurological diseases need to be investigated. Despite attempts to propel neuroprotective therapeutic approaches, numerous attempts to translate effective therapies for brain disease have been largely unsuccessful. As a good candidate for biomedical applications, hydrogels based on silk fibroin effectively amplify their advantages. The ability of nerve tissue regeneration, inflammation regulation, the slow release of drugs, antioxidative stress, regulation of cell death, and hemostasis could lead to a new approach to treating neurological disorders. In this review, we introduced the preparation of SF hydrogels and then delineated the probable mechanism of silk fibroin in the treatment of neurological diseases. Finally, we showed the application of silk fibroin in neurological diseases.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35547640 PMCID: PMC9085322 DOI: 10.1155/2022/2076680
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1The preparation of SF hydrogels.
Figure 2SF hydrogels play a 3D microenvironment akin to natural ECM.
List of the applications of SF or SF blends.
| Application | Materials | In vitro | In vivo | Cite |
|---|---|---|---|---|
| Cartilage tissue engineering | GMA/SF | Human chondrocytes | Female athymic mice, rabbits | [ |
| Bone defect repair | n-HA-GO/SF | Rabbit bone marrow mesenchymal stem cells (BMSCs) | Male mice critical-sized bone defect models | [ |
| Ligament reconstruction | SF/HA-SF | Rat BMSCs | Rabbit models of ACLR | [ |
| Wound healing | CF@GO/SF | Human fibroblast (L929) cells | Rat models of wound | [ |
| Reconstitution of cardiac function | SF | Rat quiescent ventricular cardiomyocytes | Left ventricles of rats | [ |
| Vascular remolding | SF/GT | Mouse BMSCs | / | [ |
| Trachea reconstruction | SF/CVM | Human-induced pluripotent stem cells (hiPSCs) | Porcine tracheal defect models | [ |
| Artificial cornea engineering | PVA/SF/n-HA/GP | Human corneal fibroblasts (HCFs) | / | [ |
| Enamel regeneration | SF/HA | / | / | [ |
| Hepatic tissue engineering | SF | Stem cells from human exfoliated deciduous teeth (SHED) | / | [ |
| Bladder reconstruction | SF | Adipose-derived stem cells (ASCs) | Rat bladder augmentation models | [ |
| Nucleus pulposus replacement | SF/PU | / | Rabbits | [ |
| Nerve regeneration | Collagen/SF | Human umbilical cord mesenchymal stem cells (hUC-MSCs) | Rat models of SCI | [ |
| Tumor therapy | Biliverdin/SF | / | Mice tumor models | [ |
| Drug delivery | DEX/CSNPs/SF | L929 fibroblast cell line | / | [ |
GMA: glycidyl methacrylate; n-HA: nanohydroxyapatite; GO: graphene oxide; ACLR: anterior cruciate ligament reconstruction; CF: ciprofloxacin; GT: gelatin-tyramine; CVM: collagen vitrigel membrane; GP: genipin; PU: polyurethane; SCI: spinal cord injury; DEX: dexamethasone; CSNPs: chitosan nanoparticles.
List of the published clinical trials that highlight the application of silk-based materials.
| No. | Intervention/treatment | Condition/disease | Number of participants | Compete date | Clinical trial identifier |
|---|---|---|---|---|---|
| 1 | Device: The SF patch or paper patch | Diseases of the ear and mastoid process | 60 | June 2012 |
|
| 2 | Device: HQ® matrix medical wound dressing | Donor site wound | 71 | September 2014 |
|
| 3 | Device: silk fibroin with bioactive coating layer dressing | Late complication from skin graft; | 29 | May 2015 |
|
| 4 | Bilayer scaffold composed of amniotic membrane and silk fibroin | Diabetes mellitus; Wagner ulcer grade II | 20 | February 2018 |
|
| 5 | Absorbable SF membrane | Alveolar ridge preservation after tooth extraction | 65 | December 2018 |
|
| 6 | Autologous chondrocytes seeded in SF scaffolds | Osteochondral defects | 15 | July 2019 |
|
| 7 | SF membrane combined with xenograft | K053-chronic periodontitis | 15 | December 2019 |
|
| 8 | Serioss® (SF scaffold) | Patients undergoing surgery for bone void filling | 10 | / |
|
| 9 | Device: Silk Bridge | Peripheral nerve injury digital nerve hand | 4 | March 2021 |
|
| 10 | Silk sericin dressing with collagen | Wound heal; wound surgical; donor site complication | 30 | December 2021 |
|
| 11 | Procedure: Silk microparticle filler injection | Vocal cord paralysis unilateral; dysphonia; dysphagia, oropharyngeal | 100 | September 2024 |
|
Source: data retrieved from International Clinical Trials Registry Platform.